The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
- PMID: 9336307
The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
Abstract
We describe a comprehensive retrospective analysis in which the abilities of several methods by which human pharmacokinetic parameters are predicted from preclinical pharmacokinetic data and/or in vitro metabolism data were assessed. The prediction methods examined included both methods from the scientific literature as well as some described in this report for the first time. Four methods were examined for their ability to predict human volume of distribution. Three were highly predictive, yielding, on average, predictions that were within 60% to 90% of actual values. Twelve methods were assessed for their utility in predicting clearance. The most successful allometric scaling method yielded clearance predictions that were, on average, within 80% of actual values. The best methods in which in vitro metabolism data from human liver microsomes were scaled to in vivo clearance values yielded predicted clearance values that were, on average, within 70% to 80% of actual values. Human t1/2 was predicted by combining predictions of human volume of distribution and clearance. The best t1/2 prediction methods successfully assigned compounds to appropriate dosing regimen categories (e.g., once daily, twice daily and so forth) 70% to 80% of the time. In addition, correlations between human t1/2 and t1/2 values from preclinical species were also generally successful (72-87%) when used to predict human dosing regimens. In summary, this retrospective analysis has identified several approaches by which human pharmacokinetic data can be predicted from preclinical data. Such approaches should find utility in the drug discovery and development processes in the identification and selection of compounds that will possess appropriate pharmacokinetic characteristics in humans for progression to clinical trials.
Similar articles
-
Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches.J Clin Pharmacol. 2009 May;49(5):513-33. doi: 10.1177/0091270009333209. Epub 2009 Mar 19. J Clin Pharmacol. 2009. PMID: 19299532
-
A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance.Drug Metab Dispos. 2004 Jun;32(6):603-11. doi: 10.1124/dmd.32.6.603. Drug Metab Dispos. 2004. PMID: 15155551
-
The prediction of human clearance from hepatic microsomal metabolism data.Curr Opin Drug Discov Devel. 2001 Jan;4(1):36-44. Curr Opin Drug Discov Devel. 2001. PMID: 11727321 Review.
-
Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics.Drug Metab Dispos. 2006 Jul;34(7):1255-65. doi: 10.1124/dmd.105.006619. Epub 2006 Apr 18. Drug Metab Dispos. 2006. PMID: 16621936
-
[Advances and related issues in the use of in vitro methods to predict metabolic clearance rate of new drugs].Yao Xue Xue Bao. 2007 Oct;42(10):1023-8. Yao Xue Xue Bao. 2007. PMID: 18229605 Review. Chinese.
Cited by
-
Towards More Robust Evaluation of the Predictive Performance of Physiologically Based Pharmacokinetic Models: Using Confidence Intervals to Support Use of Model-Informed Dosing in Clinical Care.Clin Pharmacokinet. 2024 Feb 15. doi: 10.1007/s40262-023-01326-3. Online ahead of print. Clin Pharmacokinet. 2024. PMID: 38361163
-
Assessing in vitro stability of remdesivir (GS-5734) and conversion to GS-441524 in feline plasma and whole blood.Vet Q. 2024 Dec;44(1):1-9. doi: 10.1080/01652176.2024.2305731. Epub 2024 Jan 30. Vet Q. 2024. PMID: 38288972 Free PMC article.
-
Preclinical evaluation of an 18F-labeled Nε-acryloyllysine piperazide for covalent targeting of transglutaminase 2.EJNMMI Radiopharm Chem. 2024 Jan 2;9(1):1. doi: 10.1186/s41181-023-00231-1. EJNMMI Radiopharm Chem. 2024. PMID: 38165538 Free PMC article.
-
A tutorial for model-based evaluation and translation of cardiovascular safety in preclinical trials.CPT Pharmacometrics Syst Pharmacol. 2024 Jan;13(1):5-22. doi: 10.1002/psp4.13082. Epub 2023 Nov 23. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 37950388 Free PMC article.
-
Complexation of histone deacetylase inhibitor belinostat to Cu(II) prevents premature metabolic inactivation in vitro and demonstrates potent anti-cancer activity in vitro and ex vivo in colon cancer.Cell Oncol (Dordr). 2023 Nov 7. doi: 10.1007/s13402-023-00882-x. Online ahead of print. Cell Oncol (Dordr). 2023. PMID: 37934338
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources